precisionlife gives us a powerful new way to study and understand complex diseases. It finds unique disease signatures that lead us quickly to the right targets in the right tissues and the right patients, and helps us understand how best to tackle disease.
+44 (0) 1865 575 170
Office hours 9am - 6pm
AI Enabled Drug Discovery
RowAnalytics’ precisionlife™ platform enables faster and deeper analysis of large genomic, clinical and phenotypic datasets. Our patented AI tools allow us to identify and validate multiple novel pathways, targets and drug compounds involved in disease in weeks not years using clinical population datasets. This provides a massive productivity and innovation gain for biopharmaceutical research. We also help healthcare providers identify responders and
non- responders in patient populations, supporting more personalized therapy selection.
Dr Steve Gardner
Chief Executive Officer
UK
C9 Glyme Court, Langford Lane
Kidlington, OX5 1LQ
USA
1 Broadway
Cambridge 02142, MA
DENMARK
Agern Allé 3
DK-2970 Hørsholm
POLAND
26 Zurawia St. Loc 10
00-515 Warsaw
Copyright RowAnalytics Ltd | Read our Privacy Policy | All Rights Reserved
+44 (0) 1865 575 170
Office hours 9am - 6pm
Steve is the visionary, a multi-disciplinary scientist who brings together cutting edge biology and chemistry with advanced computing tools.
Never afraid to innovate, Steve has over 25 years’ experience building teams to develop and commercialize ground breaking data science and informatics applications in life science and healthcare. He has gained experience working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. Steve is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. He was CEO of Synomics Ltd and led teams in Oxford Molecular, Viaken, BioWisdom and Cresset Biomolecular, supplying innovative drug discovery tools. He was involved in Oxford Molecular's IPO and acquisition of 11 international businesses. Steve has raised significant venture and
non-dilutive funding for multiple businesses in the US and UK. He is an Advisory Council member for Breast Cancer Now and UKCRC.
Previous events:
LSX World Congress – 5th - 6th February 2019
View Event
Genesis – 13th December 2018
View Event
London IP Week Panel Discussion – 11th December 2018
View Event
precisionlife is a radical new approach to complex disease analysis.
Dr Steve Gardner
Chief Executive Officer
• Multiple novel validated drug targets from existing datasets
• Targeted drug repurposing opportunities
• Improved biomarker-driven patient stratification strategies
precisionlife is delivering:
Complex diseases such as oncology, neurodegenerative, psychiatry and cardiometabolic disease don't have simple, single gene explanations. If we want to understand why some patients have higher risk or respond to drugs differently, we need to look deeper.
precisionlife has a unique ability to rapidly find all of the combinations of genomic, phenotypic and clinical features that define disease risk, prognosis and therapy response in a complex disease population. We have proven that these disease signatures can lead us to validated targets, drug discovery opportunities and better personalized medicine.
Meet the precisionlife team at these events:
AI Enabled Precision Medicine
Our deeper insights into the structure of disease populations give us a better quantitative understanding of the clinical significance of the combination of an individual patient's features. This empowers truly personal precision medicine.
• Precision medicine clinical decision support tools
• More precise personalized risk scoring
• Fully personalized digital health solutions
precisionlife is delivering:
Dr Véronique Bouchet, MBA
Chief Medical Officer
Veronique has over 30 years’ international experience in healthcare, gained across a broad range of functions and industry sectors. She is a former director of corporate strategy and head of venture strategy at AstraZeneca, where she was responsible for global corporate venturing activities, including the creation and $40M financing of the company’s first spinout, Albireo Pharma. She has also held posts in clinical research, licensing, M&A, venture capital and the NHS. This varied experience has given her an in- depth understanding of what is required to translate cutting edge science into commercial reality. Veronique is a non-executive director of International Biotechnology Trust plc. and of the Stevenage Bioscience Catalyst. She is a member of the Scientific Committee of Breast Cancer Now, and of the Council and Finance and Investment Committee of Queen Mary University London.
Véronique is the medical expert and strategic thinker with an in-depth understanding and experience of the pharmaceutical, biotech and digital health sectors.
Contact us to find out more about partnering and licensing opportunities for the precisionlife platform.
+44 (0) 1865 575 170
Office hours 9am - 6pm
RowAnalytics is proud to hold ISO27001:2013 accreditation.
Our partners and users can be confident in our information security processes.
RowAnalytics is proud to hold ISO27001:2013 accreditation. Our partners and users can be confident in our information security processes.
HealthQuake - Mind the (funding)Gap,
London –27th March 2019
A lively debate of the 'two tribes' scenario and ways in which we help fill the funding gap that could hold back progress in the domain.
Dr Marcin Pawlowski
CTO, Head Polish Operations
Marcin is the builder. As the Head of Polish Operations, Marcin builds and leads a dream R&D team of the best and the brightest data scientists and bioinformaticians.
Marcin has been involved in the core development of most of the RowAnalytics' technologies. He has hands-on expertise of the design, development and deployment of a multitude of technologies, ranging from trading systems, bioinformatics and data science. Marcin is extremely well connected to Polish and European bioinformatics and data science communities. Following graduation from the University of Warsaw, his PhD focused on applying AI methods in structural bioinformatics. During his postdoctoral research at Mathematical Medicine, Nationwide Children’s Hospital, Columbus, OH, Marcin worked on multiple projects that combined next generation sequencing, statistics, bioinformatics and biomedical research. Marcin is passionate about bringing his experience and expertise to the delivery of precision medicine.
Dr Arvind Hundal
VP, Business Development
Arvind is the commercial story teller, translating the technical stuff into a simple description of what science does and its potential for improving patient health.
Arvind is a scientist who crossed over to the business side of the healthcare industry and has in depth understanding of early drug discovery and what biotech companies need to do to commercialise their scientific research. Arvind has an international background from the UK, the Nordics and US and extensive experience gained in both the Biotechnology and Pharmaceutical sectors across multiple therapy areas. She has large pharma research and business development experience from Roche and AstraZeneca, where she was involved in spinning out Albireo Pharma. As CBO for a number of biotech companies, she has been involved in the IPO of the Danish Biotech company Zealand Pharma and the acquisition of Ziarco, a Pfizer UK spinout, by Novartis. Arvind has also closed a number of in and out licensing deals, raised investments and secured grants for emerging start-ups in the UK and Denmark.
Dr Gert L.Møller
Chief Scientific Officer
He has invented and developed new array-based solutions, which are the foundation of two of RowAnalytics’ core technologies.
Gert is an entrepreneur with over 20 years of experience of driving new innovations in AI, precision medicine and digital health by combining novel but proven software technologies. He is the principal inventor on our patents for the RACE technologies and has won a number of major awards for his innovations. He began applying RACE in 1996 across a range of industry specific and safety critical applications including product configuration (CPQ), nuclear power plant design, consumer electronics and railroad planning system. Via collaborators and scientists, engineers and commercial experts, Gert has also helped solve challenges in clinical genomics and bioinformatics including how to efficiently conduct whole genome studies based on multiple combinations of SNPs or other markers.
Dr Serdar Uckun, COO
Head US Operations
Serdar is the lateral thinker who can bridge the technology “left brain” of the company with the biology “right brain” to drive the company’s operational strategy.
Serdar is a seasoned technology executive with a diverse background in medicine, biomedical engineering, computer science, and artificial intelligence. He has worked with the best and brightest in large aerospace companies to start-ups, and from premier corporate labs to outstanding government R&D organizations. His career has taken him to the West Coast (Silicon Valley) and East Coast (Cambridge, MA) of the US as well as recent international consulting roles in the UK, Israel, and Japan. Serdar is passionate about making a lasting impact on people’s lives by helping understand and manage complex diseases. He brings his vast experience and expertise in a wide variety of disciplines together with a deep network of professional connections to solve all of RowAnalytics’ operational problems.